Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
VALANX Biotech logo — Safer, more effective ADCs and protein-drug-conjugates with...

VALANX Biotech

Safer, more effective ADCs and protein-drug-conjugates with GoldenSite™ technology

Founded 2017 Austria Austria 17 employees Seed Total: $2.30M Biotechnology, Health Care +1

General Information

Company Name VALANX Biotech
Founded Year 2017
Location Austria Austria
Employees 17
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Seed
Business Model B2B, Platform, SaaS
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with VALANX Biotech. To contact VALANX Biotech, visit valanx.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does VALANX Biotech compare?

A PDF of VALANX Biotech and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting VALANX Biotech soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About VALANX Biotech

VALANX Biotech, founded in 2017 and headquartered in Austria, is carving a niche in the Biotechnology, Health Care, and Pharmaceutical industries. The company's unique proposition lies in its GoldenSite™ technology. By offering a platform for site-specific conjugation, VALANX is reshaping how Antibody-Drug Conjugates (ADCs) are developed, ensuring reduced off-target interactions and improved efficacy.

Current focus is on developing a differentiated ADC targeting LIV-1 for combating metastatic triple-negative-breast cancer. Such innovation is aimed at fulfilling unmet needs in oncology with enhanced safety profiles and effectiveness.

The latest financial infusion, a €2.30M Seed Round on 07 November 2023, was backed by investors like SOSV, Tecnet Equity, xista science ventures, and SkyGene. The infusion is intended to accelerate the development of their pioneering ADCs, positioning VALANX as a promising player in the biotech landscape.

Business keywords: GoldenSite technology, site-specific conjugation, ADC payloads, metastatic triple-negative-breast cancer, protein-drug-conjugates, bioconjugation, structurally shielded positions, efficacy enhancement, off-target interaction reduction, LIV-1 targeting, differentiated ADCs, novel format conjugates, next generation bioconjugates

Services & Products

Optimized Protein Conjugation
ADCs Development
Therapeutic Window Enhancement
AI-Ready Dataset Preparation

Target Customers

Pharmaceutical Companies Biotech Researchers Drug Developers

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Seed €2.30M -
01 Nov 2023
Seed Undisclosed 1
SOSV
SOSV
01 Jun 2023
Convertible Note Undisclosed 1
SOSV
SOSV
01 Dec 2021
Seed Undisclosed 1
xista science ventures
xista science ventures
01 May 2020
Seed Undisclosed -
01 Jan 2020
Seed Undisclosed -
01 Sep 2018
Grant Undisclosed 1
Austria Wirtschaftsservice
Austria Wirtschaftsservice
01 Jun 2017
Spinout Undisclosed 1
Graz University of Technology
01 Mar 2017

VALANX Biotech Alternatives & Competitors

View All Alternatives
VALANX Biotech vs
Araris Biotech AG
Araris Biotech AG Switzerland

Building tomorrow's antibody-drug conjugates (ADCs)

Grant
23 employees
Biotechnology, Health Care
VALANX Biotech vs
AQEMIA
AQEMIA France

Scale drug discovery with quantum-inspired physics and generative AI

87 employees
AI, Biotechnology
VALANX Biotech vs
Biointron
Biointron China

Recombinant Antibody Expression, Delivery in 2 weeks (From Gene Sequence to Purified Antibody)

Series B
41 employees
Biotechnology, Health Care
View all alternatives

FAQ About VALANX Biotech

Safer, more effective ADCs and protein-drug-conjugates with GoldenSite™ technology
VALANX Biotech was founded in 2017.
VALANX Biotech is headquartered in Austria.
VALANX Biotech operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on GoldenSite technology, site-specific conjugation, ADC payloads and metastatic triple-negative-breast cancer. Its customers include Pharmaceutical Companies, Biotech Researchers and Drug Developers.
VALANX Biotech has a B2B, Platform and SaaS business model. Its revenue comes from Licensing, Product Sales and Service Fee.
VALANX Biotech has approximately 17 employees.
VALANX Biotech has completed 8 funding rounds, raising a total of $2.30M. The latest funding stage is Seed.
VALANX Biotech offers: Optimized Protein Conjugation, ADCs Development, Therapeutic Window Enhancement, AI-Ready Dataset Preparation.
Top alternatives and competitors to VALANX Biotech include Araris Biotech AG, AQEMIA, Biointron, Promatix Biosciences Ltd, Avilar Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
VALANX Biotech and Araris Biotech AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for VALANX Biotech, https://bouncewatch.com/company/valanx-biotech, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout